About Bioline  All Journals  Testimonials  Membership  News  Donations

Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060
EISSN: 1678-8060
Vol. 105, No. 1, 2010, pp. 45-51
Bioline Code: oc10006
Full paper language: English
Document type: Research Article
Document available free of charge

Memórias do Instituto Oswaldo Cruz, Vol. 105, No. 1, 2010, pp. 45-51

 en Antimycobacterial neolignans isolated from Aristolochia taliscana check for this species in other resources
León-Díaz, Rosalba; Meckes, Mariana; Said-Fernández, Salvador; Molina-Salinas, Gloria Maria; Vargas-Villarrea, Javier; Torres, Javier; Luna-Herrera, Julieta & Jiménez-Arellanes, Adelina


Tuberculosis (TB - Mycobacterium tuberculosis check for this species in other resources ) is an ancient infectious disease that has appeared once again as a serious worldwide health problem and now comprises the second leading cause of death resulting from a single infection. The prevalence of multidrug resistance (MDR) TB is increasing and therapeutic options for treatment are not always accessible; in fact, some patients do not respond to the available drugs. Therefore, there is an urgent need to develop novel anti-TB agents. The aim of the present study was to screen extracts of Aristolochia taliscana check for this species in other resources , a plant used in traditional Mexican medicine to treat cough and snake bites, for antimycobacterial activity. The hexanic extract of A. taliscana was tested by microdilution alamar blue assay against Mycobacterium check for this species in other resources strains and bioguided fractionation led to the isolation of the neolignans licarin A, licarin B and eupomatenoid-7, all of which had antimycobacterial activity. Licarin A was the most active compound, with minimum inhibitory concentrations of 3.12-12.5 μg/mL against the following M. tuberculosis strains: H37Rv, four mono-resistant H37Rv variants and 12 clinical MDR isolates, as well as against five non-tuberculous mycobacteria (NTM) strains. In conclusion, licarin A represents a potentially active anti-TB agent to treat MDR M. tuberculosis and NTM strains.

antimycobacterial neolignans - A. taliscana - M. tuberculosis H37Rv - MDR M. tuberculosis - non-tuberculous mycobacteria

© Copyright 2010 - Instituto Oswaldo Cruz - Fiocruz
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2018, Site last up-dated on 17-Sep-2018.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil